ERBB2 and colorectal cancer: Immune system regulation (4). High doses may shift tumor metabolism, reducing glycolysis (136, 137, 139). Intake inversely correlated with the risk of colorectal cancer (I) (140), bladder cancer (III) (141), and HR+/HER2-d breast cancer (II) (142).